Verve Therapeutics Inc
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hyper… Read more
Verve Therapeutics Inc (VERV) - Total Liabilities
Latest total liabilities as of March 2025: $140.65 Million USD
Based on the latest financial reports, Verve Therapeutics Inc (VERV) has total liabilities worth $140.65 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Verve Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Verve Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Verve Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Verve Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Farben Information Technology Co.Ltd.
SHE:300925
|
China | CN¥698.64 Million |
|
Ratos AB ser. B
LSE:0KBQ
|
UK | Skr12.85 Billion |
|
Ãlker Bisküvi Sanayi A.S.
F:A7G
|
Germany | €86.63 Billion |
|
Greatek Electronics Inc
TW:2441
|
Taiwan | NT$3.76 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥904.54 Million |
|
Sichuan Yimikang Environmental Tech Co Ltd
SHE:300249
|
China | CN¥1.47 Billion |
|
Suzhou Oriental Semiconductor Co. Ltd. A
SHG:688261
|
China | CN¥215.68 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Verve Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verve Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verve Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Verve Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $153.99 Million | +0.53% |
| 2023-12-31 | $153.19 Million | +19.41% |
| 2022-12-31 | $128.29 Million | +379.20% |
| 2021-12-31 | $26.77 Million | -81.19% |
| 2020-12-31 | $142.32 Million | +245.44% |
| 2019-12-31 | $41.20 Million | -- |